1
|
Albany C, Adra N, Snavely AC, Cary C, Masterson TA, Foster RS, Kesler K, Ulbright TM, Cheng L, Chovanec M, Taza F, Ku K, Brames MJ, Hanna NH, Einhorn LH. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann Oncol 2019; 29:341-346. [PMID: 29140422 DOI: 10.1093/annonc/mdx731] [Citation(s) in RCA: 55] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n = 622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value <0.0001. Conclusion The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.
Collapse
Affiliation(s)
- C Albany
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA.
| | - N Adra
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - A C Snavely
- PDstat, Chapel Hill, Indiana University School of Medicine, Indianapolis, USA
| | - C Cary
- Department of Urology, Indiana University School of Medicine, Indianapolis, USA
| | - T A Masterson
- Department of Urology, Indiana University School of Medicine, Indianapolis, USA
| | - R S Foster
- Department of Urology, Indiana University School of Medicine, Indianapolis, USA
| | - K Kesler
- Thoracic Division, Department of Surgery, Indiana University School of Medicine, Indianapolis, USA
| | - T M Ulbright
- Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - L Cheng
- Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - M Chovanec
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA; 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, USA; National Cancer Institute, Bratislava, Slovakia, USA
| | - F Taza
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - K Ku
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA; Division of Hematology & Medical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, USA
| | - M J Brames
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - N H Hanna
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | - L H Einhorn
- Division of Hematology & Medical Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| |
Collapse
|
2
|
Abstract
CONTEXT Testicular germ-cell tumors (GCT) are highly curable. A multidisciplinary approach, including cisplatin-based chemotherapy has resulted in cure in the majority of patients with GCT. Thus, the life expectancy of survivors will extend to many decades post-diagnosis. Late treatment toxicities associated with cisplatin-based chemotherapy may impact their future health. OBJECTIVE To systematically evaluate evidence regarding the long-term toxicity of cisplatin in GCT survivors. EVIDENCE ACQUISITION We carried out a critical review of PubMed/Medline in February 2017 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to the Consolidated Standards of Reporting Trials (CONSORT) criteria. Eighty-three publications were selected for inclusion in this analysis. EVIDENCE SYNTHESIS Included reports evaluated long-term toxicities of cisplatin-based chemotherapy in GCT survivors. Studies reporting neuro- and ototoxicity, secondary malignancies, cardiovascular, renal and pulmonary toxicities, hypogonadism and infertility were found. Seven studies (8%) reported genetic underpinnings of long-term toxicities and 3 (4%) and 14 (19%) studies correlated long-term toxicities with circulating platinum levels and cumulative dose of cisplatin, respectively. Significant risks for long-term toxicities associated with cisplatin and platinum-based regimens were reported. The cumulative dose of cisplatin and circulating platinum were reported as risk factors. Several single-nucleotide polymorphisms identified patients susceptible to cisplatin compared with wild-type individuals. CONCLUSIONS GCT survivors cured with cisplatin-based chemotherapy are at risk for long-term side-effects. Detection of single-nucleotide polymorphisms could be a valuable tool for predicting long-term toxicities. PATIENT SUMMARY Herein, this article summarizes the available evidence of long-term toxicity of cisplatin-based chemotherapy in GCT survivors and provide insights from Indiana University.
Collapse
Affiliation(s)
- M Chovanec
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA;; 2nd Department of Oncology, Faculty of Medicine, Comenius University, Bratislava, Slovakia;; National Cancer Institute, Bratislava, Slovakia
| | - M Abu Zaid
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA
| | - N Hanna
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA
| | - N El-Kouri
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA
| | - L H Einhorn
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA
| | - C Albany
- Division of Hematology Oncology, Indiana University Simon Cancer Center, Indianapolis, USA;.
| |
Collapse
|
3
|
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27:v119-v133. [PMID: 27664248 DOI: 10.1093/annonc/mdw270] [Citation(s) in RCA: 356] [Impact Index Per Article: 44.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Affiliation(s)
- F Roila
- Medical Oncology, Santa Maria Hospital, Terni, Italy
| | - A Molassiotis
- School of Nursing, The Hong Kong Polytechnic University, Hong Kong, China SAR
| | - J Herrstedt
- Department of Oncology, Odense University Hospital, Odense, Denmark
| | - M Aapro
- Clinique de Genolier, Multidisciplinary Oncology Institute, Genolier, Switzerland
| | - R J Gralla
- Albert Einstein College of Medicine, Jacobi Medical Center, New York
| | - E Bruera
- Department of Palliative, Rehabilitation and Integrative Medicine, UT MD Anderson Cancer Center, Houston
| | - R A Clark-Snow
- The University of Kansas Cancer Center, Westwood, Kansas, USA
| | - L L Dupuis
- Department of Pharmacy and Research Institute, The Hospital for Sick Children, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada
| | - L H Einhorn
- Division of Hematology-Oncology, Simon Cancer Center, Indiana University, Indianapolis, USA
| | - P Feyer
- Department of Radiation Oncology, Vivantes Clinics, Neukoelln, Berlin, Germany
| | - P J Hesketh
- Lahey Health Cancer Institute, Burlington, USA
| | - K Jordan
- Department of Hematology/Oncology, Martin-Luther-University Halle-Wittemberg, Halle, Germany
| | - I Olver
- Sansom Institute for Health Research, University of South Australia, Adelaide, Australia
| | - B L Rapoport
- Medical Oncology Centre of Rosebank, Johannesburg, South Africa
| | - J Roscoe
- Department of Surgery, University of Rochester Medical Center, Rochester, USA
| | - C H Ruhlmann
- Department of Oncology, Odense University Hospital, Odense, Denmark
| | - D Walsh
- Academic Department of Palliative Medicine, Our Lady's Hospice and Care Services, Dublin, Ireland
| | - D Warr
- Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada
| | - M van der Wetering
- Department of Paediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, The Netherlands
| | | |
Collapse
|
4
|
Adra N, Althouse SK, Liu H, Brames MJ, Hanna NH, Einhorn LH, Albany C. Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014. Ann Oncol 2016; 27:875-9. [PMID: 26861605 DOI: 10.1093/annonc/mdw045] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2015] [Accepted: 01/22/2016] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Based on the risk stratification from the International Germ Cell Cancer Collaborative Group (IGCCCG), only 14% of patients with metastatic germ-cell tumors (GCT) had poor-risk disease with a 5-year progression-free survival (PFS) rate of 41% and a 5-year overall survival (OS) rate of only 48%. This analysis attempts to identify prognostic factors for patients with poor-risk disease. PATIENTS AND METHODS We conducted a retrospective analysis of all patients with GCT diagnosed and treated at Indiana University from 1990 to 2014. Clinical and pathological characteristics were available for all patients and all of them were treated with cisplatin-etoposide-based chemotherapy. Cox proportional hazards models were used to target significant predictors of disease progression and mortality. A significance level of 5% was used in the analysis. RESULTS We identified 273 consecutive patients with poor-risk GCT (PRGCT). Median follow-up time was 8 years (range 0.03-24.5). The 5-year PFS and OS rates were 58% [95% confidence interval (CI) 51% to 63%] and 73% (95% CI 67% to 78%), respectively. In multivariate survival analyses, multiple risk factors were associated with disease progression, including liver metastasis, brain metastasis, primary mediastinal nonseminomatous GCT (PMNSGCT), and elevation in logarithmic β-hCG. Significant predictors of mortality were PMNSGCT [hazard ratio (HR) 4.63, 95% CI 2.25-9.56; P < 0.001], brain metastasis (HR 3.30, 95% CI 1.74-6.23; P < 0.001), and increasing age (HR 1.03, 95% CI 1.01-1.06; P = 0.02). CONCLUSIONS Patients with PMNSGCT, brain metastasis, or with increasing age are at higher risk of death than their counterparts. This contemporary cohort (1990-2014) of 273 patients with PRGCT had improved PFS and OS outcomes than those from the historical IGCCCG group of patients (1975-1990).
Collapse
Affiliation(s)
- N Adra
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - S K Althouse
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - H Liu
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - M J Brames
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - N H Hanna
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - L H Einhorn
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| | - C Albany
- Division of Hematology/Oncology and Biostatistics, Melvin & Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, USA
| |
Collapse
|
5
|
Jain A, Brames MJ, Vaughn DJ, Einhorn LH. Phase II clinical trial of oxaliplatin and bevacizumab in refractory metastatic germ cell tumors (GCT). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4579] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Brames MJ, Picus J, Yu M, Johnston EL, Bottema B, Williams CE, Einhorn LH. Phase III, double-blind, placebo-controlled, crossover study evaluating a 5HT3 antagonist plus dexamethasone with or without aprepitant in patients with germ cell tumor receiving 5-day cisplatin combination chemotherapy: A Hoosier Oncology Group (HOG) study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Feldman DR, Einhorn LH, Quinn DI, Horwich A, Loriot Y, Joffe JK, Vaughn DJ, Flechon A, Hajdenberg J, Pande AU, Liu K, Gorbatchevsky I, Motzer RJ. A phase II multicenter evaluation of ARQ 197 monotherapy in patients with relapsed or refractory germ cell tumors (GCTs). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4638] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Mulherin BP, Brames MJ, Einhorn LH. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplants. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Asirwa FC, Einhorn LH. Salvage therapy with high-dose chemotherapy (HDCT) and peripheral blood stem cell transplant (PBSCT) in patients with primary mediastinal nonseminomatous germ cell tumors (PMNSGCT). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Pant-Purohit M, Brames MJ, Abonour R, Einhorn LH. Tumor marker rise during second course high-dose chemotherapy in recurrent testicular cancer: Outcome analysis. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Albany C, Jalal SI, Turchi J, Wu J, Yu Z, Einhorn LH. A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: Correlative analysis of a trial from the Hoosier Oncology Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e17517] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Jalal SI, Bufill JA, Masters GA, Somaiah N, Koneru K, McClean J, Sanborn RE, Wu J, Yu Z, Einhorn LH. A phase I study of amrubicin (AMR) and cyclophosphamide in patients with advanced solid organ malignancies: A trial from the Hoosier Oncology Group. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl 5:v232-43. [PMID: 20555089 DOI: 10.1093/annonc/mdq194] [Citation(s) in RCA: 454] [Impact Index Per Article: 32.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Roila
- Department of Medical Oncology, S. Maria University Hospital, Terni, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Lorch A, Mollevi C, Kramar A, Einhorn LH, Necchi A, Massard C, DeGiorgi U, Flechon A, Margolin KA, Beyer J. Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4513] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Ramasubbaiah R, Brames J, Johnston EL, Einhorn LH, J.aughn D, Perkins SM. Phase II study of oxaliplatin (O) and bevacizumab (B) chemotherapy in refractory germ cell tumors (GCT). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15054] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Foster R, Ehrlich Y, Ulbright TM, Cheng L, Bihrle R, Beck SD, Andreoiu M, Brames MJ, Einhorn LH. Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with retroperitoneal lymph node dissection and PNET specific chemotherapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5081 Background: Malignant transformation of teratoma to PNET is a rare entity. Surgical resection has been the mainstay of therapy because these tumors are not curable with cisplatin based chemotherapy. We report long-term survival and potential cure with retroperitoneal lymph node dissection (RPLND) and PNET specific chemotherapy. Methods: Retrospective review of 75 patients (pts) with PNET in the testis or at distant metastasis treated from Jan 1988 to Dec 2007. 74 had RPLND as part of initial treatment or at relapse. PNET specific chemotherapy consisted of cyclophosphamide, doxorubicin, vincristine alternating with ifosfamide and etoposide. Available PNET specimens were tested for the Ewing's sarcoma (EWS) translocation using a FISH-based method. Results: The median follow-up was 40 months (range 2 to 235). 27 pts presented with clinical stage I disease. 18 underwent primary RPLND with PNET in the retroperitoneum in 5. 4 are dead of disease (DOD). 9 elected surveillance or adjuvant chemotherapy. 8 relapsed with PNET. 4 are DOD. 48 pts presented with metastatic disease. 20 are DOD, 24 have no evidence of disease (NED) and 4 are alive with disease. 50 of 75 pts had PNET documented metastasis with an estimated 5 years disease specific survival of 47%. 10 of these were treated with PNET specific chemotherapy for unresectable disease. 8 of the 10 achieved objective response with the duration of response ranging from 4 to 73 months. 2 pts are NED. 2 additional pts were treated with PNET specific chemotherapy as adjuvant to RPLND. Both are continuously NED. Specimens from 14 pts were tested for the EWS translocation, 2 were positive. Conclusions: Malignant transformation of teratoma to PNET carries an adverse prognosis. RPLND is an integral part of the therapeutic strategy. PNET specific chemotherapy, adjuvant to RPLND or for treatment of unresectable disease followed by surgery, may result in long-term survival and potential cure. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Foster
- Indiana University, Indianapolis, IN
| | | | | | - L. Cheng
- Indiana University, Indianapolis, IN
| | - R. Bihrle
- Indiana University, Indianapolis, IN
| | | | | | | | | |
Collapse
|
17
|
Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of chemotherapy-induced remissions in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5029 Background: There is controversy concerning management of patients (pts) with nonseminomatous germ cell tumor (NSGCT) who obtain a chemotherapy-induced complete radiographic (<1cm node diameter) and serologic remission (CR). It has been our policy not to recommend retroperitoneal lymph nodes dissection (RPLND). Proponents of mandatory RPLND cite a 20% to 30% rate of residual microscopic tumor, mostly teratoma, despite achieving CR. Methods: Retrospective analysis of 141 patients with metastatic NSGCT who obtained CR to cisplatin-based first-line chemotherapy. All were observed without RPLND. Included were 78 consecutive pts treated between Jan 1987 and Sept 1994. Additionally included were 63 pts recruited in 4 prospective trials between Oct 1984 and Apr 2005. Seven pts were lost to follow-up (FU) after <2 year. Results: At a median a FU of 15 years (range 3 months to 23.8 years), 12 pts recurred and 4 are dead of disease (DOD). The estimated 15 year recurrence free and disease specific survival was 90% and 97% respectively. The estimated 15 years recurrence free survival for 109 pts with good risk and 32 pts with intermediate or poor risk was 95% and 73% respectively (p = 0.001). Five pts recurred >2 years (range 3–13 years). All 5 are currently disease free. Six pts recurred in the RP and 2 are DOD. Six pts recurred outside the RP. Two of these 6 are DOD. Conclusions: Pts obtaining CR after primary chemotherapy can be safely observed without RPLND. Relapses are rare and potentially curable with further treatment. No significant financial relationships to disclose.
Collapse
|
18
|
Kruter LE, Kesler KA, Yu M, Hammoud ZT, Rieger KM, Einhorn LH. The predictive value of serum tumor markers for pathologic findings after chemotherapy for primary mediastinal nonseminomatous germ cell tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5087] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Radaideh SM, Cook V, Kesler KA, Einhorn LH. Outcome following resection for patients with primary mediastinal nonseminomatous germ cell tumors and rising serum tumor markers post-chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.5038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Strother RM, Jones D, Li L, Younger A, Einhorn LH, Williams S, Sweeney CJ. Effect of the C3435T genetic polymorphism in MDR1 on etoposide pharmacokinetics. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2500] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Jalal SI, Bhatia S, Einhorn LH, Ansari RH, Bechar N, Govindan R, Koneru K, Bedano PM, Wu J, Hanna NH. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): A safety, feasibility and efficacy trial from the Hoosier Oncology Group. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Mina LA, Neubauer MA, Ansari RH, Govindan R, Einhorn LH, Fisher W, Bruetman D, Chowhan NM, Johnson C, Hanna NH. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023—Updated results. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7519] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Doyle DM, Einhorn LH. Delayed toxicity of whole brain radiotherapy (WBRT) in germ cell tumor (GCT) patients with central nervous system (CNS) metastases. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15511 Background: CNS metastases are uncommon in GCT. Incidence is 2–3% and is usually associated with extensive pulmonary metastases and/or high serum human chorionic gonadotropin levels. CNS metastases have been managed with WBRT and concomitant cisplatin-based combination chemotherapy. Our prior publication did not observe serious CNS toxicity (Int J Rad Oncol Biol Phys 22:17–22, 1991). Methods: We observed 5 patients with delayed CNS toxicity. Initial diagnosis was 1981 through 2003. Median age 23 years (range 21–34). All 5 patients had advanced disease by the International Germ Cell Consensus Collaborative Group. Three of five patients had CNS metastases at the time of diagnosis, and two patients relapsed with CNS metastases. These 5 patients received WBRT 4,000–5,000 cGy in 18- 28 fractions concurrently with cisplatin-based chemotherapy. Results: All five patients developed delayed symptoms consistent with progressive multifocal leukoencephalopathy (PMLE), including seizures, hemiparesis, expressive and receptive aphasia, cranial neuropathies including facial droop, tremors, headaches, blindness, dementia, decreased level of consciousness, ataxia, and parasthesias. Median time from WBRT to CNS symptoms was 72 months (range 9–228 months). Brain imaging revealed multiple abnormalities consistent with gliosis and diffuse cerebral atrophy. One patient was diagnosed with glioblastoma multiforme in the area of radiation-induced gliosis. 3 of 5 patients had progressive symptoms, and the other 2 had stable symptoms. Treatment with surgery and steroids had modest benefit. The PMLE resulted in significant debility in all five patients, resulting in death (2 patients), loss of work, steroid-induced morbidity, and recurrent hospitalizations. Conclusions: WBRT is not innocuous in young patients with GCT and can cause late CNS toxicity. We are now cautious about the use of WBRT and reserve it for multiple CNS metastases that are symptomatic or resistant to chemotherapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- D. M. Doyle
- Indiana Univ School of Medcn, Camby, IN; Indiana Univ School of Medcn, Indianapolis, IN
| | - L. H. Einhorn
- Indiana Univ School of Medcn, Camby, IN; Indiana Univ School of Medcn, Indianapolis, IN
| |
Collapse
|
24
|
Azar JM, Einhorn LH, Schneider BP. Is the blood-brain barrier relevant in metastatic germ cell tumors? J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.15618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
15618 Background: Metastatic germ cell tumors (GCT) are highly curable. Central Nervous System (CNS) recurrence can terminate a complete remission in other chemosensitive tumors such as small cell lung cancer due to the blood brain barrier (BBB). We document that the BBB can also be relevant in GCTs despite dramatic chemosensitivity. Methods: We present five cases of CNS only relapse in GCTs. None of these five patients had CNS metastases at the start of chemotherapy. Results: We have identified five unique patients from our large series of metastatic testicular cancer patients treated with chemotherapy. These patients were rendered free of disease with cisplatin- based chemotherapy only to relapse in the brain alone ( Table 1 ). This included one patient with good risk disease by the International Germ Cell Collaborative Group staging system (Patient #5). All patients had pulmonary metastases at diagnosis and a component of embryonal carcinoma. Three patients are alive without evidence of disease (NED) at 19, 32 and 8 months. One patient died of his disease (DOD) and one patient is alive with disease (AWD). Conclusion: The blood brain barrier is relevant in metastatic testicular cancer. [Table: see text] No significant financial relationships to disclose.
Collapse
|
25
|
Papiani G, Einhorn LH. Salvage chemotherapy with high-dose carboplatin plus etoposide and autologous peripheral blood stem cell transplant in male pure choriocarcinoma: a retrospective analysis of 13 cases. Bone Marrow Transplant 2007; 40:235-7. [PMID: 17563738 DOI: 10.1038/sj.bmt.1705697] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Choriocarcinoma of testes is a very rare tumor with poor prognosis, usually presenting with high serum level of human chorionic gonadotropin (hCG>50,000 mIU/ml) and advanced hematogenous metastases. Data with salvage chemotherapy has been sparse, with few long-term survivors. Between April 1996 and October 2004, 184 patients with germ cell tumor were treated at Indiana University with salvage high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplant. Thirteen had pure choriocarcinoma or choriocarcinoma syndrome (normal testes by palpation and ultrasound, normal serum alpha-fetoprotein, advanced hematogenous metastases and high level hCG). All patients had progressed following one or two lines of cisplatin combination therapy. HDCT regimen was carboplatin 700 mg/m(2) and etoposide 750 mg/m(2) intravenously given for 3 consecutive days. A second course was given after hematopoietic recovery, usually 3-4 weeks later. The median survival was 19 months (range 5-90). Six patients (46%) are alive and continuously disease free (cNED) at a median follow-up of 37 months (range 19-75). One additional patient who relapsed after HDCT and was treated with third line chemotherapy followed by two surgical resections of choriocarcinoma is currently alive NED at +90 months from HDCT. Long-term disease-free survival and potential cure is possible with HDCT in choriocarcinoma patients that progressed after standard cisplatin combination therapy.
Collapse
Affiliation(s)
- G Papiani
- Department of Hematology and Oncology, Istituto Oncologico Romagnolo, Ravenna City Hospital, Ravenna, Italy.
| | | |
Collapse
|
26
|
Bedano PM, Neubauer M, Ansari R, Govindan R, Einhorn LH, Bruetman D, White A, Breen T, Juliar B, Hanna N. Phase III study of cisplatin (P) plus etoposide (E) with concurrent chest radiation (XRT) followed by docetaxel (D) vs. observation in patients (pts) with stage III non-small cell lung cancer (NSCLC): An interim toxicity analysis of consolidation therapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7043] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7043 Background: Concurrent chemo radiotherapy is the standard treatment for pts with unresectable stage III NSCLC. A previously reported phase II study (Gandara et al J Clin Oncol 2003) suggests that consolidation D after concurrent PE/XRT may further improve survival. HOG LUN01–24, is an ongoing phase III clinical trial comparing chemo radiation. A preliminary analysis of the differences in toxicities between PE/XRT with or without consolidation D was performed. Methods: Eligible pts had previously untreated, unresectable stage III NSCLC, ECOG PS 0–1 at time of study entry (and PS 0–2 at the time of randomization), ≤ 5% weight loss in preceding 3 months, FEV-1 > 1 L. Treatment consisted of P 50 mg/m2 days 1, 8, 29, 36 with E 50 mg/m2 days 1–5 and 29–33, given concurrently with chest XRT to 5,940 cGy (180 cGy/day) beginning on day 1. Non-progressive pts were randomized (4–8 weeks after completing PE/XRT) to receive D 75 mg/m2 iv every 21 days for 3 cycles vs. observation. We report an interim toxicity analysis associated to consolidation D. Results: From 3/02 to 12/05 220 have been registered and 149 pts have been randomized to consolidation D (n=73) or observation (n=76). Median age was 63.6 years (range 33–86); male/female 34.1%/65.9%; PS 0/1 at study entry 59.1%/40.9%; stage III A/B 40.6%/59.4%; 50.2% had FEV-1 > 2 (range 1–4.2); 44.3% were current smokers. Randomized pts have PS 0/1/2 44.3%/53%/2.7. Selected grade 3/4 toxicities associated to D include: neutropenia 23.3%, febrile neutropenia 8.2%, and pulmonary toxicity 9.6%. In addition, 26.7% of pts had dose modifications or delays on D arm, 45.2% had at least one grade 3/4 toxicity and 20.5% were hospitalized due to D-related toxicity, including 4 pts (5.5%) whose death was considered therapy related. Conclusions: Concurrent PE/XRT followed by consolidation D is associated with a high rate of grade 3/4 toxicities and hospitalizations, including treatment-related deaths. Updated toxicity data will be presented at the ASCO meeting. Whether consolidation D confers a survival advantage is not yet known. [Table: see text]
Collapse
Affiliation(s)
- P. M. Bedano
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - M. Neubauer
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - R. Ansari
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - R. Govindan
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - L. H. Einhorn
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - D. Bruetman
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - A. White
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - T. Breen
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - B. Juliar
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| | - N. Hanna
- Indiana University School of Medicine, Indianapolis, IN; US Oncology, Houston, TX; Northern Indiana Cancer Research Consortium, South Bend, IN; Washington University School of Medicine, St. Louis, MO; Center for Cancer Care, Goshen, IN; Hoosier Oncology Group, Indianapolis, IN
| |
Collapse
|
27
|
Gandhi L, Harding M, Neubauer M, Langer CJ, Crawford J, Moore M, Rooney J, Ross H, Einhorn LH, Johnson BE, Lynch TJ. A phase II study of the safety and efficacy of the MDR inhibitor VX-710 combined with doxorubicin and vincristine in small cell lung cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.17001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17001 Background: Tumors with multidrug resistance (MDR) frequently show upregulation of efflux proteins MDR protein (MRP-1) and P-glycoprotein (Pgp). MDR represents a major obstacle to successful chemotherapy treatment and can be reversed in Pgp or MRP1-expressing cells by the MDR inhibitor VX-710. A phase II study was designed to evaluate the safety/tolerability and efficacy of VX-710 combined with doxorubicin (D) and vincristine (V) in patients (pts) with relapsed SCLC. Methods: Eligible pts had progressive, measurable disease and a PS <2 after response to 1st-line chemotherapy. Stage I safety evaluation was done with planned expansion to a second stage if 9 responses were confirmed in the first 35 pts. Pts were treated with VX-710 (120 mg/m2/h) for 72 hours with D (45 mg/m2) and V (1.4 mg/m2) given 4 hours after the start of VX-710. Pts were treated q 21 days until progression or intolerable adverse events (AEs). Severe neutropenia was noted in the first 15 pts, so the protocol was amended to include prophylactic G-CSF or ciprofloxacin. Interim analysis was performed after 36 pts were treated. Results: 36 pts were enrolled from 12/98 to 12/00. Neutropenia was the major toxicity, occurring in 25/36 (69%) pts. This was more severe (30% vs. 20% grade 4) and occurred earlier (58% vs. 38% in cycle 1) among the 15 pts enrolled prior to an amendment requiring neutropenia prophylaxis vs. those enrolled afterward. Other common treatment-related AE’s: asthenia (53%), nausea (50%), constipation (44%), alopecia (42%), dyspnea (42%), anemia (42%). 67% were grade 1 or 2 in severity. Four pts died on study or within 30 days of termination: 2 from infections likely related to therapy and 2 from disease progression. Among 32 evaluable pts, 7 (22%) had partial responses; 6 of these sustained responses through 6 cycles (with one response lasting 3 years). Three additional pts had unconfirmed responses. Median survival was 6 months (95% CI 4–7 months). Conclusions: The addition of VX-710 to D and V therapy did not improve anti-tumor activity or survival. Hematologic toxicity was severe, causing 2 pt deaths from neutopenic fever. Although there were some durable responses, response criteria were not met to proceed with stage 2. Further development with VX-710 has since stopped. [Table: see text]
Collapse
Affiliation(s)
- L. Gandhi
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - M. Harding
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - M. Neubauer
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - C. J. Langer
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - J. Crawford
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - M. Moore
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - J. Rooney
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - H. Ross
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - L. H. Einhorn
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - B. E. Johnson
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| | - T. J. Lynch
- Dana-Farber Cancer Institute, Boston, MA; Vertex Pharmaceuticals, Cambridge, MA; Kansas City Cancer Center, Overland Park, KS; University of Pennsylvania, Philadelphia, PA; Duke University, Durham, NC; Georgia Cancer Specialists, Decatur, GA; Fallon Clinic, Worcester, MA; Providence Cancer Center, Portland, OR; Indiana University School of Medicine, Indianapolis, IN; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
28
|
Einhorn LH, Williams S, Abonour R. Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4549] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4549 Background: We began studies with HDCE for patients (pts.) with recurrent GCTs 20 years ago. During the past decade, better supportive care and use of PBSCT allowed outpatient therapy and more rapid hematopoietic recovery between the 2 courses of HDCE. Methods: Retrospective review of 184 consecutive pts. treated with HDCE at Indiana University from 2–96 to 12–04. Late relapse (> 2 years from prior therapy) and primary mediastinal non-seminomatous germ cell tumor pts. were not offered HDCE. Cytoreduction with 0–2 courses of vinblastine + ifosfamide + cisplatin preceded HDCE. C dosage was 700 mg/M2 × 3 and E 750 mg/M2 × 3. A second course was given after hematologic recovery. Results: Toxicity was as previously described (JCO 18:3346, 2000). There were 3 drug- related mortalities. An additional 3 patients developed AML (2 fatal), and 1 glioma following CNS XRT for metastases. 11 pts. did not receive second course (8 due to progression or HDCE mortality). Median time to second course HDCE was 28 days (range 20 to 42). 116 of 184 pts. are alive and continuously (cont) NED (63%) with median followup 42 months (range 11 to 118). 113 (97%) of these are 12+ months NED. 5 additional pts. are currently NED with further therapy. Results are tabulated below. Conclusions: HDCE has a high cure rate with acceptable toxicity as salvage therapy for GCT pts. [Table: see text] [Table: see text]
Collapse
|
29
|
Abstract
18618 Background: Chemotherapy agents are classified by their degree of emetogenicity. Agents with high or moderate emetogenicity are treated with a 5HT3 antagonist + dexamethasone to mitigate acute and delayed chemotherapy-induced nausea and vomiting. Intravenous etoposide (E) has low probability of nausea and/or vomiting. However, at the 2004 Perugia International Antiemetic Consensus meeting, oral E was listed as a moderately emetogenic drug (Supp Care Cancer 13:80–84, 2005). Daily oral E has been used to treat refractory germ cell cancer. We prospectively evaluated the emetic potential of daily oral etoposide in this patient (pt.) population. Methods: Between 8/03 and 12/05, 13 male pts. with refractory germ cell cancer were treated with single agent daily oral E 50 mg/M2 day × 21 days every 4 weeks. All had progressed following cisplatin combination chemotherapy and had previously received high dose chemotherapy with carboplatin + E (intraveneously) with peripheral blood stem cell transplant. Median age was 35 (range 14 to 54). No pt. received prophylactic antiemetics. Pts. completed a 6 question Multinational Association Supportive Care Cancer (MASCC) antiemetic tool each day they received E. Intensity and duration of nausea were recorded, with 0 being none and 10 being most severe. Additionally, pts. were asked if they experienced vomiting. The number of vomiting episodes as well as any antiemetic medications were recorded. Data on 25 pts. will be presented and we currently have information on 13 pts. Results: 13 pts. completed the MASCC form. Only 2 pts. required antiemetic support. 1 pt. experienced emesis × 1 on day 1 and 1 pt. experienced emesis × 1 on day 11. 1 pt. experienced nausea on days 9 through 20 with a MASCC rating of 3–6. 1 pt. documented nausea day 1 through 21 with a MASCC rating of 1–3. 2 pts. experienced a MASCC rating of 1 of their nausea, 1 pt. on day 1 and 1 pt. on day 2. Overall, 8 of 13 pts. had no nausea or vomiting despite the absence of any antiemetics and 2 other patients had only minimal nausea for a single day. Conclusions: Daily oral E has only a low probability of emesis and does not require prophylactic antiemetics. [Table: see text]
Collapse
|
30
|
Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, McClean J, Chowhan N, Hanna N, Calley C, Yu M. A phase II trial of olanzapine and palonosetron for the prevention of chemotherapy induced nausea and vomiting (CINV). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8608 Background: Olanzapine has been shown to be a safe and effective agent for the prevention of CINV in chemotherapy naïve cancer patients. Palonosetron has been approved for the prevention of acute CINV and for the prevention of delayed CINV in patients receiving moderately emetogenic chemotherapy (MEC). Methods: A phase II trial was performed for the prevention of CINV in chemotherapy naïve patients using the combination of olanzapine and palonosetron. The regimen was 10 mg of oral olanzapine, 0.25 mg of intravenous palonosetron, and dexamethasone (20 mg for highly emetogenic and 8 mg for moderately emetogenic chemotherapy) on the day of chemotherapy, day 1, and 10 mg/day of oral olanzapine alone on days 2–4 after chemotherapy. Forty patients (median age 60 yrs, range 38–84; 22 females; ECOG PS 0,1) consented to the protocol and all were evaluable. Results: The percentage of patients with a complete response (CR) (no emesis, no rescue) was 100% for the acute period (24 h post chemotherapy), 75% for the delayed period (days 2–5 post chemotherapy), and 75% for the overall period (0–120 h) for eight patients receiving highly emetogenic chemotherapy (HEC) (cisplatin > 70 mg/m2). CR was 97% for the acute period, 75% for the delayed period, and 72% for the overall period in 32 patients receiving MEC (doxorubicin, >50mg/m2). In the patients receiving HEC, the percentage of patients without nausea (0, scale 0–10, M. D. Anderson Symptom Inventory) was 100% in the acute period, 50% in the delayed period, and 50% in the overall period. In patients receiving MEC, the percentage without nausea was 100% in the acute period, 78% in the delayed period, and 78% in the overall period. There were no Grade 3 or 4 toxicities and no significant pain, fatigue, disturbed sleep, memory changes, dyspnea, lack of appetite, drowsiness, dry mouth, mood changes or restlessness experienced by the patients. CR and control of nausea in subsequent cycles of chemotherapy (35 patients, cycle 2; 31 patients cycle 3; 23 patients, cycle 4) were equal to or greater than cycle one. Conclusions: The combination of olanzapine and palonosetron with dexamethasone given only on the day of chemotherapy was safe and highly effective in controlling acute and delayed CINV in patients receiving HEC and MEC. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. M. Navari
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - L. H. Einhorn
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - P. J. Loehrer
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - S. D. Passik
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - J. Vinson
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - J. McClean
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - N. Chowhan
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - N. Hanna
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - C. Calley
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| | - M. Yu
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; Hoosier Oncology Group, Indianapolis, IN
| |
Collapse
|
31
|
Brames MJ, Roth BJ, Dreicer R, Bubalo J, Nichols C, Cullen MT, Degroot T, Einhorn LH. Palonosetron (PALO) + dexamethasone (DEX) for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving multiple-day cisplatin CT for germ cell cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8607] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8607 Background: Fractionated cisplatin is highly emetogenic; despite 5HT3 receptor antagonists + DEX, patients still experience acute and delayed CINV. PALO, a novel 5HT3 antagonist, is superior to conventional 5HT3 antagonists in protecting patients from emesis with a 0.25-mg IV dose prior to single-day CT. To assess the efficacy and safety of PALO in 40 patients with germ cell tumors receiving multiple-day cisplatin-based CT, a phase II multicenter study is being conducted. Methods: Adult men receiving 5-day cisplatin-based (20 mg/m2/d) CT received PALO 0.25 mg IV 30 min before CT on days 1, 3, and 5 and DEX 20 mg qd (po or IV 30 min before CT) on days 1–2; 8 mg po bid on days 6–7; and 4 mg po bid on day 8. Rescue medication was allowed at investigator discretion. Endpoints included emetic episodes (EE), nausea intensity, and rescue use, recorded in diaries for 9 consecutive 24-h periods. Interference with functioning due to nausea on a 4-point scale (none, a little bit, quite a bit, very much) was assessed with the validated Osoba nausea module on days 1, 5, and 10; safety was assessed at all follow-up encounters. Results: To date, 32 patients are evaluated, median age 35 years, 81% CT-naïve. Prior to CT, 97% of patients reported no more than a little interference with functioning from nausea. Most patients reported no significant interference with functioning due to nausea on days 1–4 of cisplatin (73% reported none/a little bit) and days 5–9 (87% none/a little bit). PALO + DEX was well tolerated; treatment-related adverse events were mild-moderate headache (18.8%), constipation (6.3%), and abdominal pain (3.1%), none serious. Conclusions: Three doses of PALO + 5 doses of DEX over an 8-day period effectively prevented both emesis and significant nausea in the majority of patients with germ cell tumors receiving multiple-day cisplatin-based CT. This regimen appears to be an improvement over historical CINV control. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. J. Brames
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - B. J. Roth
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - R. Dreicer
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - J. Bubalo
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - C. Nichols
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - M. T. Cullen
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - T. Degroot
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| | - L. H. Einhorn
- Indiana University, Indianapolis, IN; Vanderbilt-Ingram Cancer Center, Nashville, TN; Cleveland Clinic, Cleveland, OH; Oregon Health and Science University, Portland, OR; MGI Pharma, Inc., Bloomington, MN
| |
Collapse
|
32
|
Lewis DA, Brames MJ, Einhorn LH. Can patients (pts.) with refractory germ cell tumors (GCT) be cured after progression following high dose chemotherapy (HDCT) with tandem transplant? Results with paclitaxel + gemcitabine. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4588 Background: A previously published ECOG study of paclitaxel (P) plus gemcitabine (G) in refractory germ cell tumors achieved a 21% response rate (6 of 28 pts.) (JCO 20:1859, 2002). Two patients are continuously NED for 4+ years. Neither had prior HDCT. High dose salvage chemotherapy with carboplatin + etoposide and peripheral blood stem cell transplant has curative potential. Subsequent chemotherapy after progression following HDCT has only rarely achieved durable remission. We have retrospectively reviewed pts. treated at Indiana University with P + G after failure to cure with initial cisplatin combination chemotherapy and salvage HDCT (± other salvage regimens). Methods: 184 patients received salvage HDCT from February 1996 to December 2004. After further progression, 33 pts. were treated with P 100 mg/M2 over 1 hour and G 1000 mg/M2 over 30 minutes days 1, 8, and 15 every 4 weeks for a maximum of 6 courses. Pts. were ineligible if they received prior P or G. 26 pts. received P + G as 3rd line, 6 as 4th line and 1 as 5th line chemotherapy. Results: Toxicity was primarily myelosuppression and neuropathy, as previously described with P + G (JCO 20:1859, 2002). There was no treatment related mortality. 10 of 33 pts. achieved objective response including 4 partial (2 to 6 months duration) and 6 complete responses (C.R.). 4 of the 6 C.R.s are continuously NED with P + G alone at 14+, 34+, 44+, and 45+ months from start of P + G. One additional C.R. is currently NED 54+ months after P + G, with 2 subsequent resections of carcinoma. Conclusions: Long-term disease free survival and potential cure is possible with P + G in this patient population after progression following HDCT. [Table: see text]
Collapse
|
33
|
Hammoud ZT, Kesler KA, Ferguson MK, Battafarrano RJ, Bhogaraju A, Hanna N, Govindan R, Mauer AA, Yu M, Einhorn LH. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. Dis Esophagus 2006; 19:69-72. [PMID: 16643172 DOI: 10.1111/j.1442-2050.2006.00542.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A variety of strategies, using chemotherapy, radiation therapy, and surgical resection have been employed in the treatment of locally advanced esophageal cancer. No strategy has proven superior, and poor long-term survival is anticipated. A survival benefit has been suggested for patients who achieve a pathologic complete response (pCR) following neoadjuvant chemoradiation therapy. We examined the collective results at three institutions of patients who achieved a pCR following neoadjuvant chemoradiation therapy. A retrospective, chart-based review was conducted. Kaplan-Meier calculations were used to determine overall and disease-free survival. Between 1995 and 2002, 229 patients were treated with neoadjuvant chemoradiation followed by surgery as a planned approach for locally advanced esophageal cancer. Forty-one patients (18%) demonstrated pCR and were the focus of this study. Histology was adenocarcinoma in 29, squamous in 10, and adenosquamous/undifferentiated in two patients. Forty patients were staged by endoscopic ultrasound prior to neoadjuvant therapy and all demonstrated a T-stage of 2 or higher, while 19 had evidence of nodal metastasis. Four patients died in the perioperative period. The remaining patients have been followed for an average of 46 months. Overall survival at 5 years was 56.4% and a median survival has not been reached. Esophageal cancer patients who demonstrate a pCR following neoadjuvant chemoradiation are a select subset who demonstrate excellent long-term survival. Identification of clinical variables or biomarkers predictive of pCR may therefore optimize treatment strategies of patients with locally advanced esophageal cancer.
Collapse
Affiliation(s)
- Z T Hammoud
- Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 2006; 52:93-7. [PMID: 16488055 DOI: 10.1016/j.lungcan.2005.12.002] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2005] [Revised: 12/05/2005] [Accepted: 12/14/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND Gefitinib has demonstrated activity in patients with non-small cell lung cancer (NSCLC). Clinical trials have not demonstrated a relationship between response to gefitinib and over-expression of the epidermal growth factor receptor (EGFR). Although, EGFR is not over-expressed in small cell lung cancer (SCLC), we postulated that gefitinib might affect tumor growth through other mechanisms. Agents that are active in NSCLC usually are also effective in SCLC. METHODS The primary objective was to assess the clinical control rate: complete response (CR) partial response (PR) and stable disease (SD > 90 days), of gefitinib in patients with chemo-resistant and chemo-sensitive small cell cancers. Eligibility criteria included pathologic proof of a neuroendocrine tumor, especially small cell cancer, Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2, prior treatment with one or two prior chemotherapy regimens and adequate end-organ function. Patients received gefitinib, 250 mg p.o. daily until disease progression or intolerable side effects. RESULTS From April 2003 to March 2004, 19 patients were enrolled. Small cell lung cancer accounted for 18 of the 19 patients and one patient had metastatic Merkel cell carcinoma. Twelve patients (63%) had chemo-sensitive disease, defined as progression greater than three months from completion of prior chemotherapy; 7 (37%) had chemo-refractory disease; 13 (68%) had one prior chemotherapy regimen. Other patient characteristics: mean age 64 years (range 52-79 years); ECOG PS 0/1/2 = 7/9/3, M:F = 9:10. Grade 3 toxicities included: fatigue in three patients (15.8%), pulmonary toxicities in three (15.8%) and one patient (5.3%) each with hyperglycemia or pain. Four patients had grade four toxicities: one patient (5.3%) with fatigue and three patients (15.8%) with dyspnea. There were no patients with grade 3 or 4 rash or diarrhea. Two patients had stable disease (<90 days) and 17 had progressive disease as their best response. This study was a two-stage design and because the continuing criterion for stage one was not met, stage 2 was not performed. Median time to progression (TTP) was 50 days (95% CI = 21-58 days). One year overall survival (OS) was 21% (95% CI = 6-45.6%). CONCLUSION Although gefitinib has activity in select patients with NSCLC, this study failed to demonstrate benefit in patients with small cell lung cancer.
Collapse
Affiliation(s)
- A M Moore
- Indiana University School of Medicine, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Bedano PM, Brames MJ, Williams SW, Einhorn LH. A phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4526] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Shafqat A, Einhorn LH, Hanna N, Sledge GW, Hanna A, Juliar BE, Monahan P, Bhatia S. Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment. Ann Oncol 2005; 16:1545-50. [PMID: 15919683 DOI: 10.1093/annonc/mdi267] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND To understand the pathogenesis of fatigue in cancer, we conducted a cross-sectional study using Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-Fatigue (FACT-F) instruments to measure fatigue and assessed laboratory studies. PATIENTS AND METHODS 174 patients with cancer, who had undergone treatment within the last six months, answered the questionnaires and the Brief Version Zung Self-Rating Depression Scale (BZSDS). Blood samples were drawn for hemoglobin, albumin, thyroid stimulating hormone (TSH), dehydroepiandrosterone-sulfate (DHEAS) and tumor necrosis factor-alpha (TNF- alpha). Testosterone levels were checked in male patients. RESULTS Clinically significant fatigue with BFI > or =4 was present in 52.0% of patients. Measurement of laboratory parameters revealed the following: DHEAS levels <80 mcg/dl in males and <36 mcg/dl in females=54.1%; BZSDS scores > or =27=20.1%; testosterone levels <200 ng/dl=26.4% of male patients. Significant correlations were noted between BFI and FACT-F, albumin levels, hemoglobin levels and BZSDS scores. In addition, for male patients BFI correlated with DHEAS and testosterone levels. In multiple linear regression, hemoglobin, BZSDS scores and current opioid use were associated with response BFI. For male patients, DHEAS <80 mcg/dl, increased BZSDS and testosterone <200 ng/dl were associated with increased BFI. CONCLUSION Fatigue is common in this population and BFI correlates with more extensive measurements. Abnormalities such as decreased testosterone and DHEAS may lead to interventions that can be therapeutically exploited.
Collapse
Affiliation(s)
- A Shafqat
- Division of Hematology-Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Loehrer PJ, Wang W, Aisner S, Bonomi P, Einhorn LH, Langer CJ, Green MR, Livingston RB, Johnson DH, Schiller J. Long-term follow-up of patients with locally advanced or metastatic thymic malignancies: The Eastern Cooperative Oncology Group (ECOG) experience. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. J. Loehrer
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - W. Wang
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - S. Aisner
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - P. Bonomi
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - L. H. Einhorn
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - C. J. Langer
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - M. R. Green
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - R. B. Livingston
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - D. H. Johnson
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| | - J. Schiller
- Indiana University Cancer Center, Indianapolis, IN; Dana Farber Cancer Institue, Boston, MA; New Jersey Medical School, Newark, NJ; Rush University, Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; Medical University of South Carolina, Charlston, SC; University of Washington, Seattle, WA; Vanderbilt University, Nashville, TN; University of Wisconsin, Madison, WI
| |
Collapse
|
38
|
Navari RM, Einhorn LH, Loehrer PJ, Passik SD, Vinson J, Mayer ML, Pletcher W, McClean J. A phase II trial of olanzapine for the prevention of chemotherapy induced nausea and vomiting (CINV). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. M. Navari
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - L. H. Einhorn
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - P. J. Loehrer
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - S. D. Passik
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - J. Vinson
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - M. L. Mayer
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - W. Pletcher
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| | - J. McClean
- University of Notre Dame, Notre Dame, IN; Indiana University, Indianapolis, IN; University of Kentucky, Lexington, KY; Hoosier Oncology Group, Indianapolis, IN
| |
Collapse
|
39
|
Kesler KA, Wilson JL, Cosgrove JA, Messiha A, Brooks JA, Clouse TR, Fineberg NS, Einhorn LH. Surgical “salvage” therapy for intrathoracic chemorefractory metastases from non-seminomatous germ cell cancer of testicular origin: An institutional retrospective review. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- K. A. Kesler
- Indiana University School of Medicine, Indianapolis, IN
| | - J. L. Wilson
- Indiana University School of Medicine, Indianapolis, IN
| | | | - A. Messiha
- Indiana University School of Medicine, Indianapolis, IN
| | - J. A. Brooks
- Indiana University School of Medicine, Indianapolis, IN
| | - T. R. Clouse
- Indiana University School of Medicine, Indianapolis, IN
| | | | - L. H. Einhorn
- Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
40
|
Shafqat A, Titzer ML, Sweeney CJ, Giesler RB, Hanna A, Porter J, Selbe K, Daggy J, Einhorn LH. A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.8148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | - A. Hanna
- Indiana University, Indianapolis, IN
| | - J. Porter
- Indiana University, Indianapolis, IN
| | - K. Selbe
- Indiana University, Indianapolis, IN
| | - J. Daggy
- Indiana University, Indianapolis, IN
| | | |
Collapse
|
41
|
Potter DA, Li L, Badve S, Kesler K, Rieger K, Hanna N, McDonald C, Edenberg H, Einhorn LH, Mitra R. Decreased T cell infiltration and lymphocyte/dendritic cell/monocyte gene expression as well as increased Cyp3A5 mRNA predicts early recurrence of non-small cell lung cancer (NSCLC) following surgical resection. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. A. Potter
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - L. Li
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - S. Badve
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - K. Kesler
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - K. Rieger
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - N. Hanna
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - C. McDonald
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - H. Edenberg
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - L. H. Einhorn
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| | - R. Mitra
- Indiana University, Indianapolis, IN; Regenstrief Institute, Indianapolis, IN
| |
Collapse
|
42
|
Brooks JA, Werner E, Jain NP, Helft PR, Zon RT, Fineberg NS, Leblanc J, McHenry L, Einhorn LH, Kesler KA. A retrospective analysis to identify variables predictive of achieving a pCR after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J. A. Brooks
- Indiana University School of Medicine, Indianapolis, IN
| | - E. Werner
- Indiana University School of Medicine, Indianapolis, IN
| | - N. P. Jain
- Indiana University School of Medicine, Indianapolis, IN
| | - P. R. Helft
- Indiana University School of Medicine, Indianapolis, IN
| | - R. T. Zon
- Indiana University School of Medicine, Indianapolis, IN
| | | | - J. Leblanc
- Indiana University School of Medicine, Indianapolis, IN
| | - L. McHenry
- Indiana University School of Medicine, Indianapolis, IN
| | - L. H. Einhorn
- Indiana University School of Medicine, Indianapolis, IN
| | - K. A. Kesler
- Indiana University School of Medicine, Indianapolis, IN
| |
Collapse
|
43
|
Abstract
Ifosfamide has always had significant single-agent activity in patients with germ cell tumors. We first began studies of cisplatin + ifosfamide combination chemotherapy as salvage chemotherapy in 1982. The regimen of etoposide (VP-16) + ifosfamide + cisplatin (VIP) was initially utilized as third-line chemotherapy. Even in this refractory setting, we were able to cure a small cohort of patients. Ifosfamide-cisplatin combination chemotherapy then became a standard second-line chemotherapy program, and achieved a 25% cure rate. Subsequent phase III studies compared VIP to bleomycin + etoposide + cisplatin (BEP) as initial chemotherapy. Although the results of the ifosfamide-based regimen were slightly better, there was no statistically significant difference and BEP was less toxic. However, for individual patients with concern for bleomycin-induced pulmonary fibrosis, VIP remains an attractive first-line regimen.
Collapse
Affiliation(s)
- L H Einhorn
- Division of Hematology/Oncology and Walther Cancer Institute, Indianapolis, IN 46202, USA.
| |
Collapse
|
44
|
Soule SE, Miller KD, Porcu P, Ansari R, Fata F, McClean JW, Zon R, Sledge GW, Einhorn LH. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Ann Oncol 2002; 13:1612-5. [PMID: 12377650 DOI: 10.1093/annonc/mdf283] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Docetaxel and estramustine exert anti-tumor effects by inhibiting microtubule function. In vitro data suggest synergism with this combination. This phase II study evaluated the response rate and toxicity of docetaxel and estramustine in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS Patients were treated with docetaxel 35 mg/m(2) on day 2 and estramustine phosphate 280 mg p.o. tds days 1-3 weekly for 3 of 4 weeks, for a maximum of six treatment cycles. RESULTS Thirty-nine patients were enrolled between August 1999 and March 2001; 36 were eligible. Of 31 evaluable patients, responses were observed in 15 patients (47%); two patients (6%) obtained a complete response. Median time to treatment failure was 6 months; median survival was 1 year. Thromboembolic toxicity occurred in 11% of patients: three experienced deep venous thromboses and one had a fatal pulmonary embolism. Myelosuppression was minimal with this regimen. CONCLUSIONS Despite modest activity in metastatic breast cancer, the toxicity observed with the combination of estramustine and docetaxel precludes the routine use of this combination in the treatment of breast cancer. Further studies using this compound in metastatic breast cancer are not warranted.
Collapse
Affiliation(s)
- S E Soule
- Hoosier Oncology Group, Walther Cancer Institute and Division of Hematology/Oncology, Indiana University, Indianapolis, IN, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Sweeney CJ, Monaco FJ, Jung SH, Wasielewski MJ, Picus J, Ansari RH, Dugan WM, Einhorn LH. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 2002; 13:435-40. [PMID: 11996476 DOI: 10.1093/annonc/mdf029] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The purpose was to evaluate the combined anti-microtubular regimen of vinorelbine and estramustine phosphate (EMP) in hormone refractory prostate cancer. PATIENTS AND METHODS Weekly vinorelbine 20 mg/m2 (or 15 mg/m2 if a history of prior pelvic radiotherapy) was combined with EMP at 280 mg orally tds for 3 days (the day before, the day of and the day after vinorelbine infusion). After 8 weeks of therapy the combination was given every other week. RESULTS From February 1998 to February 1999, 23 men were enrolled with a median age of 69 years (range 50-83 years). The median prostate-specific antigen (PSA) at entry was 160 ng/ml (range 0-802 ng/ml). A median of 13 weeks of therapy was administered and the median follow-up was 14.8 months. Eleven patients (48%) had lower extremity edema requiring diuretic therapy, two (9%) had grade 2 granulocytopenia and four patients [17%; 95% confidence interval (CI) 5% to 39%] had a thromboembolic episode. There was no treatment-related mortality. Fifteen of 21 patients (71%; 95% CI 49% to 89%) had at least a 50% decrease in the PSA for at least 2 months with a median time to serologic progression of 3.5 months (range 0.75-10.5 months). One of eight patients (12.5%; 95% CI 0% to 53%) with measurable disease had a confirmed partial response. The estimated median survival was 15.1 months and the actual one year overall survival was 71% (95% CI 51% to 88%). CONCLUSIONS Weekly vinorelbine with short course oral EMP is an active regimen as evaluated by rate of PSA response, time to progression and median survival. However, the toxicities of EMP, even when given as a short course, are still problematic.
Collapse
Affiliation(s)
- C J Sweeney
- Hoosier Oncology Group, Indianapolis IN, USA
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Hanna NH, Sandier AB, Loehrer PJ, Ansari R, Jung SH, Lane K, Einhorn LH. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol 2002; 13:95-102. [PMID: 11863118 DOI: 10.1093/annonc/mdf014] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND We performed this phase III study to determine whether the addition of 3 months of oral etoposide in non-progressing patients with extensive small-cell lung cancer (SCLC) treated with four cycles of etoposide plus ifosfamide plus cisplatin (VIP) improves progression-free survival (PFS) or overall survival. PATIENTS AND METHODS Patients with extensive SCLC with a Karnofsky performance score (KPS) > or =50, adequate renal function and bone marrow reserve were eligible. Patients with CNS metastasis were eligible and received concurrent whole-brain radiotherapy. All patients received etoposide 75 mg/m2, ifosfamide 1.2 g/m2 and cisplatin 20 mg/m2 intravenously on days 1-4 every 3 weeks for four cycles. Non-progressing patients were randomized to oral etoposide 50 mg/m2 for 21 consecutive days every 4 weeks for three courses versus no further therapy until progression. RESULTS From September 1993 to June 1998, 233 patients were entered and treated with VIP with 144 non-progressing patients subsequently randomized to oral etoposide (n = 72) or observation (n = 72). Minimum follow up for all patients is 2 years. Toxicity with oral etoposide was mild. There was an improvement in median PFS favoring the maintenance arm of 8.23 versus 6.5 months (P = 0.0018). There was a trend towards an improvement in median (12.2 versus 11.2 months), 1-year (51.4% versus 40.3%), 2-year (16.7% versus 6.9%) and 3-year (9.1% versus 1.9%) survival (P = 0.0704) favoring the maintenance arm. CONCLUSIONS Three months of oral etoposide in non-progressing patients with extensive SCLC was associated with a significant improvement in PFS and a trend towards improved overall survival.
Collapse
Affiliation(s)
- N H Hanna
- Department of Medicine, Indiana University Medical Center, Indianapolis, USA.
| | | | | | | | | | | | | |
Collapse
|
47
|
Einhorn LH. ASCO 2001 Presidential address. J Clin Oncol 2001; 19:1S-5S. [PMID: 11560963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Affiliation(s)
- L H Einhorn
- Indiana Cancer Pavilion, Indianapolis, IN 46202, USA
| |
Collapse
|
48
|
Gordon MS, Battiato LA, Finch D, Goulet R, Einhorn LH. Dramatic response of teratoma-associated non--germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor. Am J Clin Oncol 2001; 24:269-71. [PMID: 11407397 DOI: 10.1097/00000421-200106000-00012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A patient with nonseminomatous germ cell cancer, treated with standard chemotherapy, subsequently developed a pathologically confirmed metastatic undifferentiated adenocarcinoma (non-germ-cell elements) arising from residual teratoma. Disease was present in both lobes of the liver and was deemed unresectable at the time of presentation. The patient was treated on a National Cancer Institute-sponsored institutional protocol with all-trans retinoic acid. After 60 days of oral therapy at a dose of 150 mg/m2/d (50 mg/m2 three times daily), the patient was found to have complete radiologic resolution of his hepatic metastases. He subsequently underwent surgery and his complete response was pathologically confirmed.
Collapse
Affiliation(s)
- M S Gordon
- Department of Medicine, Indiana University School of Medicine, Indianapolis, USA
| | | | | | | | | |
Collapse
|
49
|
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-82. [PMID: 11387360 DOI: 10.1200/jco.2001.19.11.2875] [Citation(s) in RCA: 477] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To prospectively evaluate the effectiveness, safety, and clinical benefits of once-weekly epoetin alfa therapy as an adjunct to chemotherapy in anemic cancer patients. PATIENTS AND METHODS A total of 3,012 patients with nonmyeloid malignancies who received chemotherapy were enrolled onto this multicenter, open-label, nonrandomized study conducted in 600 United States community-based practices. Patients received epoetin alfa 40,000 U once weekly, which could be increased to 60,000 U once weekly after 4 weeks dependent on hemoglobin response. Treatment was continued for a maximum of 16 weeks. RESULTS Among the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases in hemoglobin levels, decreases in transfusion requirements, and improvements in functional status and fatigue as assessed by the linear analog scale assessment (energy level, ability to perform daily activities, and overall quality of life) and the anemia subscale of the Functional Assessment of Cancer Therapy-Anemia questionnaire. Improvements in quality-of-life parameters correlated significantly (P <.001) with increased hemoglobin levels. The direct relationship between hemoglobin and quality-of-life improvement was sustained during the 16-week study period, which is similar to findings of large community-based trials of three-times-weekly dosing. Once-weekly epoetin alfa was well tolerated, with most adverse events attributed to the underlying disease or concomitant chemotherapy. CONCLUSION The results from this large, prospective, community-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decreases transfusion requirements, and improves quality of life in patients with cancer and anemia who undergo concomitant chemotherapy. Based on the results of this study, the clinical benefits and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are similar to those observed in the historical experience with the three-times-weekly dosage schedule.
Collapse
Affiliation(s)
- J L Gabrilove
- Mount Sinai Medical Center, New York, NY 10029, USA.
| | | | | | | | | | | |
Collapse
|
50
|
Ganjoo KN, Foster RS, Michael H, Donohue JP, Einhorn LH. Germ cell tumor associated primitive neuroectodermal tumors. J Urol 2001; 165:1514-6. [PMID: 11342908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
PURPOSE This retrospective review was done to assess the prognosis and response in patients presenting with primitive neuroectodermal tumor admixed with germ cell tumor. MATERIALS AND METHODS Of the 40 patients treated at our institution from 1984 to 1999, 15 had initial stage I and 25 had initial metastatic disease. Median followup after the diagnosis was 25 months (range 4 to 142). RESULTS Of the 40 patients 15 presented with clinical stage I disease, including 9 treated with retroperitoneal lymph node dissection and 6 who elected surveillance. Seven of the 9 patients had normal lymph nodes and all continuously had no evidence of disease. Two of the 9 patients had lymph nodes involved with teratoma with or without primitive neuroectodermal tumor. Retroperitoneal relapse in 5 of the 6 patients on surveillance was treated with cisplatin based chemotherapy followed by post-chemotherapy retroperitoneal lymph node dissection. Residual primitive neuroectodermal tumor was noted in 4 of the 5 patients and only 3 of 6 are currently without disease at a median followup of 17 months (range 15 to 69). A total of 25 patients presented with metastatic disease, of whom 23 underwent cisplatin based chemotherapy. Only 3 patients achieved complete remission with chemotherapy alone and 2 of the 3 subsequently relapsed. Of the remaining 20 patients 16 underwent post-chemotherapy retroperitoneal lymph node dissection, including 11 with primitive neuroectodermal tumor in the resected specimen. Two of these 11 patients have continuously had no evidence of disease, while an additional 3 currently have no evidence of disease after further therapy. Teratoma was present in the resected specimen in 5 of 16 patients, of whom 2 have continuously had no evidence of disease, while an additional 2 currently have no evidence of disease after further surgical resection. Therefore, 11 of 25 patients who presented with metastatic disease currently have no evidence of disease at a median followup of 19 months (range 2 to 111). CONCLUSIONS Primitive neuroectodermal tumor in the orchiectomy specimen has adverse prognostic significance. This condition in the retroperitoneum is potentially curable by retroperitoneal lymph node dissection but rarely eradicated by chemotherapy. Therefore, we recommend retroperitoneal lymph node dissection for all clinical stage I cases with primitive neuroectodermal tumor in the orchiectomy specimen. Patients who present with metastatic primitive neuroectodermal tumor should be treated aggressively with surgical resection as an integral part of the therapeutic strategy.
Collapse
Affiliation(s)
- K N Ganjoo
- Division of Hematology-Oncology, Department of Medicine, Indiana University Medical Center, Indianapolis, Indiana, USA
| | | | | | | | | |
Collapse
|